Does NIVOLUMAB Cause Agranulocytosis? 165 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 165 reports of Agranulocytosis have been filed in association with NIVOLUMAB (OPDIVO). This represents 0.2% of all adverse event reports for NIVOLUMAB.
165
Reports of Agranulocytosis with NIVOLUMAB
0.2%
of all NIVOLUMAB reports
25
Deaths
125
Hospitalizations
How Dangerous Is Agranulocytosis From NIVOLUMAB?
Of the 165 reports, 25 (15.2%) resulted in death, 125 (75.8%) required hospitalization, and 52 (31.5%) were considered life-threatening.
Is Agranulocytosis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for NIVOLUMAB. However, 165 reports have been filed with the FAERS database.
What Other Side Effects Does NIVOLUMAB Cause?
Death (11,216)
Malignant neoplasm progression (9,363)
Off label use (5,208)
Diarrhoea (4,692)
Fatigue (3,709)
Pyrexia (3,454)
Intentional product use issue (3,297)
Rash (2,816)
Nausea (2,805)
Decreased appetite (2,619)
What Other Drugs Cause Agranulocytosis?
CLOZAPINE (1,766)
CYCLOPHOSPHAMIDE (1,242)
RITUXIMAB (1,154)
SULFAMETHOXAZOLE\TRIMETHOPRIM (797)
PANTOPRAZOLE (599)
METHOTREXATE (550)
SODIUM (549)
EPIRUBICIN (491)
METAMIZOLE (438)
DOCETAXEL (436)
Which NIVOLUMAB Alternatives Have Lower Agranulocytosis Risk?
NIVOLUMAB vs NIVOLUMAB\RELATLIMAB-RMBW
NIVOLUMAB vs NIZATIDINE
NIVOLUMAB vs NOMEGESTROL
NIVOLUMAB vs NORDAZEPAM
NIVOLUMAB vs NOREPINEPHRINE